Novo Nordisk A/S (NYSE:NVO) Given “Sell” Rating at Deutsche Bank Aktiengesellschaft

Novo Nordisk A/S (NYSE:NVO)‘s stock had its “sell” rating restated by stock analysts at Deutsche Bank Aktiengesellschaft in a research note issued on Tuesday.

Other research analysts have also recently issued reports about the company. BMO Capital Markets reissued a “market perform” rating on shares of Novo Nordisk A/S in a research report on Tuesday. Weiss Ratings raised shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. Wall Street Zen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Berenberg Bank set a $47.00 target price on shares of Novo Nordisk A/S and gave the stock a “hold” rating in a report on Wednesday, August 12th. Finally, Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Three investment analysts have rated the stock with a Buy rating, seventeen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $61.94.

Novo Nordisk A/S Stock Up 0.6%

NVO stock traded up $0.24 during midday trading on Tuesday, hitting $38.55. The company’s stock had a trading volume of 11,776,206 shares, compared to its average volume of 17,066,984. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.66. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $64.16. The company’s fifty day moving average price is $45.28 and its 200 day moving average price is $43.86. The stock has a market capitalization of $172.11 billion, a P/E ratio of 9.42, a PEG ratio of 1.27 and a beta of 0.74.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. The company had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%. As a group, equities research analysts predict that Novo Nordisk A/S will post 3.54 EPS for the current year.

Hedge Funds Weigh In On Novo Nordisk A/S

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. QRG Capital Management Inc. raised its stake in shares of Novo Nordisk A/S by 23.0% during the second quarter. QRG Capital Management Inc. now owns 175,187 shares of the company’s stock valued at $8,398,000 after acquiring an additional 32,756 shares during the last quarter. Envestnet Portfolio Solutions Inc. grew its position in shares of Novo Nordisk A/S by 9.8% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 16,205 shares of the company’s stock valued at $777,000 after buying an additional 1,444 shares during the last quarter. Envestnet Asset Management Inc. increased its stake in shares of Novo Nordisk A/S by 1.8% in the second quarter. Envestnet Asset Management Inc. now owns 4,031,114 shares of the company’s stock valued at $193,250,000 after buying an additional 71,684 shares during the period. State Street Corp raised its position in shares of Novo Nordisk A/S by 0.6% during the second quarter. State Street Corp now owns 5,869,834 shares of the company’s stock worth $284,565,000 after acquiring an additional 32,641 shares during the last quarter. Finally, Wellington Altus USA Inc. bought a new position in shares of Novo Nordisk A/S during the second quarter worth about $115,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo signed an exclusive licensing agreement with Hengrui Pharma for HRS-1596, a phase 1-ready, once-weekly oral GLP-1/GIP drug candidate. The deal is worth up to $2.6 billion, including $300 million upfront, and expands Novo’s pipeline of oral obesity treatments and potential alternatives to daily pills. China’s Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug
• Positive Sentiment: A real-world analysis presented at a medical meeting found that patients switching from Wegovy or Eli Lilly’s Zepbound injections to Novo’s daily Wegovy pill lost about 4% of their body weight over three months. The data supports demand for a more convenient oral option and helps Novo defend its position in the obesity market. People switching to Novo’s Wegovy pill from obesity injections kept losing weight in real-world study
• Positive Sentiment: Novo reported real-world evidence suggesting patients who increased Ozempic to 2 mg had a 6% lower risk of major cardiovascular events than patients who switched to Lilly’s Mounjaro. While observational rather than a head-to-head clinical trial, the finding strengthens Ozempic’s differentiation. Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly’s Mounjaro
• Positive Sentiment: Recent CagriSema phase 3 data showed 12.4% weight loss after 60 weeks in a type 2 diabetes study, improving confidence in another late-stage obesity asset. Novo is also pursuing longer-acting delivery technology through its Nanexa collaboration. Novo Nordisk Just Beat Lilly in a Trial
• Neutral Sentiment: Novo’s share-repurchase program remains in progress, with a broader authorization of up to DKK 15 billion over 12 months. Buybacks may provide technical support, but they do not resolve the company’s growth and competitive challenges. Novo Nordisk share repurchase programme
• Negative Sentiment: Investors remain concerned about an “uninspiring” growth outlook and competition from Lilly. Lilly has claimed its oral obesity treatment, Foundayo, delivers greater weight loss and better blood-sugar control than higher-dose Ozempic, while some analysts continue to rate NVO only “Hold.” Novo Nordisk Gives Uninspiring Outlook

About Novo Nordisk A/S

Novo Nordisk A/S is a Denmark-based global pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes injectable and oral medicines for diabetes, including insulin products and the GLP-1 therapies Ozempic and Rybelsus, as well as the obesity treatment Wegovy.

The company also develops and markets products for rare blood disorders, including hemophilia, along with growth hormone therapies and hormone replacement treatments.